Government-Owned Inventions; Availability for Licensing, 17268-17269 [2017-07058]

Download as PDF 17268 Federal Register / Vol. 82, No. 67 / Monday, April 10, 2017 / Notices needs of professionals caring for children in disasters since the 2011 National Center for Disaster Medicine and Public Health Conference on this topic. We will post modifications to the agenda on the NACCD May 5, 2017 meeting Web page, which is located at https://www.phe.gov/naccd. Availability of Materials: We will post all meeting materials prior to the meeting on the NACCD May 5, 2017 meeting Web page located at https:// www.phe.gov/naccd. Procedures for Providing Public Input: Members of the public may attend the teleconference using a toll-free call-in phone number available on the NACCD Web site at https://www.phe.gov/naccd. We encourage members of the public to provide written comments that are relevant to the NACCD teleconference prior to May 5, 2017. Send written comments by email via the ‘‘Contact Us’’ link on https://www.phe.gov/naccd with ‘‘NACCD Public Comment’’ in the subject line. The NACCD will respond to comments received by close-ofbusiness April 28, 2017, during the meeting. Dated: April 4, 2017. George W. Korch Jr., Acting Assistant Secretary for Preparedness and Response. [FR Doc. 2017–07052 Filed 4–7–17; 8:45 am] BILLING CODE P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact Peter Soukas at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, asabaliauskas on DSK3SPTVN1PROD with NOTICES SUMMARY: VerDate Sep<11>2014 20:02 Apr 07, 2017 Jkt 241001 MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. A Full-Length Infectious cDNA Clone of Zika Virus From the 2015 Epidemic in Brazil as a Genetic Platform for Studies of Virus-Host Interactions and Vaccine Development Description of Technology: An arthropod-borne virus, Zika virus (ZIKV), has recently emerged as a major human pathogen. Associated with complications during perinatal ´ development and Guillain-Barre syndrome in adults, ZIKV raises new challenges for understanding the molecular determinants of flavivirus pathogenesis. This underscores the necessity for the development of a reverse genetic system based on an epidemic ZIKV strain. This technology relates to the generation and characterization in cell cultures of an infectious cDNA clone of ZIKV isolated from the 2015 epidemic in Brazil. The cDNA-derived ZIKV replicated efficiently in a variety of cell lines, including those of both neuronal and placental origin. It was observed that the growth of cDNA-derived virus was attenuated compared to the growth of the parental isolate in most cell lines, which correlates with substantial differences in sequence heterogeneity between these viruses that were determined by deep-sequencing analysis. Moreover, these results indicate that caution should be exercised when interpreting the results of reverse-genetics experiments in attempts to accurately predict the biology of natural viruses. Finally, a Vero cell-adapted cDNA clone of ZIKV was generated that can be used as a convenient platform for studies aimed at the development of ZIKV vaccines (live attenuated and inactivated) and therapeutics. This technology is available for licensing nonexclusively in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. This technology is further described in Tsetsarkin et al., ‘‘A Full-Length Infectious cDNA Clone of Zika Virus from the 2015 Epidemic in Brazil as a Genetic Platform for Studies of VirusHost Interactions and Vaccine Development,’’ mBio. 2016 Jul–Aug; 7(4): e01114–16. Published online 2016 Aug 23. doi: 10.1128/mBio.01114–16. Potential Commercial Applications: PO 00000 Frm 00091 Fmt 4703 Sfmt 4703 • Diagnostics • Vaccines • Development of therapeutics Competitive Advantages: • Use in development of flavivirus vaccines • Virus growth in various cell lines • Developing and developed world research tool Development Stage: • Research materials Inventors: Alexander Pletnev (NIAID), Konstantin Tsetsarkin (NIAID). Intellectual Property: HHS Reference No. E–114–2017/0. Licensing Contact: Peter Soukas, J.D., 301–594–8730; peter.soukas@nih.gov. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize vaccine(s) or diagnostics for prophylaxis against flavivirus infections. For collaboration opportunities, please contact Peter Soukas, J.D., 301–594–8730; peter.soukas@nih.gov. Dated: March 23, 2017. Suzanne Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2017–07057 Filed 4–7–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The inventions listed below are owned by an agency of the U.S. Government and are available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the U.S. patent applications listed below may be obtained by communicating with the indicated licensing contact James M. Robinson at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and SUMMARY: E:\FR\FM\10APN1.SGM 10APN1 Federal Register / Vol. 82, No. 67 / Monday, April 10, 2017 / Notices asabaliauskas on DSK3SPTVN1PROD with NOTICES Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496– 2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: Technology descriptions follows. Compositions and Methods for Detecting Loa Loa Description of Technology: Loa loa is a filarial nematode estimated to infect 3–13 million people in Central and Western Africa. In parts of Africa, mass administration of ivermectin is common for onchocerciasis and lymphatic filariasis control. However, some individuals infected with Loa loa microfilariae in high densities are known to experience post-ivermectin severe adverse events, such as encephalopathy, coma, or even death. Therefore, diagnostic tools that can accurately identify and differentiate Loa loa microfilariae from other filarial infections are needed. Microscopic evaluation of blood samples is the only current diagnostic method used to detect Loa loa microfilaremia in endemic areas, and is impractical for widespread screening. Molecular based assays are useful and are quantitative, but require the use of sophisticated instrumentation. The inventors analyzed samples from Loa loa infected patients and uninfected controls, and have identified Loa loa microfilaria-specific antigens. The pending application claims a variety of means of detecting these antigens. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. Potential Commercial Applications: • Diagnostics Competitive Advantages: • Highly specific to Loa loa microfilariae • Highly sensitive • Both diagnostic and quantitative • Works with blood, urine, or saliva sample Development Stage: • Pre-Clinical Inventors: Thomas B. Nutman, NIAID, NIH; Sasisekhar Bennuru, NIAID, NIH; and Papa Makhtar Drame, NIAID, NIH. Publications: Drame, Papa, et al. 2016. Identification and Validation of Loa loa Microfilaria-Specific Biomarkers: A Rational Design Approach Using Proteomics and Novel Immunoassays. mBio, vol. 7 no. 1 e02132–15. Intellectual Property: HHS Reference No. E–140–2015/0—US Provisional VerDate Sep<11>2014 20:02 Apr 07, 2017 Jkt 241001 Patent Application No. 62/153,654 filed April 28, 2015; PCT Patent Application No. PCT/US2016/029673 filed April 28, 2016. Licensing Contact: James M. Robinson, 301–761–7542; James.Robinson4@nih.gov. Collaborative Research Opportunity: The Technology Transfer and Intellectual Property Office (TTIPO) is seeking parties interested in collaborative research to further develop, evaluate or commercialize a diagnostic means for detecting Loa loa microfilaria-specific antigens. For collaboration opportunities, please contact James M. Robinson, 301–761– 7542; James.Robinson4@nih.gov. Dated: March 28, 2017. Suzanne Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2017–07058 Filed 4–7–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Office of the Director; Notice of Charter Renewal In accordance with Title 41 of the U.S. Code of Federal Regulations, Section 102–3.65(a), notice is hereby given that the Charter for the Center for Scientific Review Advisory Council (CSRAC) was renewed for an additional two-year period on March 31, 2017. It is determined that the CSRAC is in the public interest in connection with the performance of duties imposed on the National Institutes of Health by law, and that these duties can best be performed through the advice and counsel of this group. Inquiries may be directed to Jennifer Spaeth, Director, Office of Federal Advisory Committee Policy, Office of the Director, National Institutes of Health, 6701 Democracy Boulevard, Suite 1000, Bethesda, Maryland 20892 (Mail Code 4875), Telephone (301) 496– 2123, or spaethj@od.nih.gov. Dated: April 4, 2017. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. 17269 DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Heart, Lung, and Blood Institute; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Sleep Disorders Research Advisory Board. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. Name of Committee: Sleep Disorders Research Advisory Board. Date: June 22–23, 2017. Time: June 22, 2017, 1:00 p.m. to 5:00 p.m. Agenda: Update on NIH sleep disorders research programs and initiatives, updates on sleep related activities from selected Federal Agency partners, and discussion of the NIH Sleep Disorders Research Plan. Place: National Institutes of Health, Two Rockledge Center, Conference Room 9100/ 9104, 6701 Rockledge Drive, Bethesda, MD 20892. Time: June 23, 2017, 8:00 a.m. to 3:00 p.m. Agenda: Discussion and updates on the NIH Sleep Disorders Research Plan, and potential directions for inter-agency coordination activities. Place: National Institutes of Health, Two Rockledge Center, Conference Room 9100/ 9104, 6701 Rockledge Drive, Bethesda, MD 20892. Contact Person: Michael J. Twery, Ph.D., Director, National Center on Sleep Disorders Research, Division of Lung Diseases, National Heart, Lung, and Blood Institute, National Institutes of Health, 6701 Rockledge Drive, Suite 10170, Bethesda, MD 20892–7952, 301– 435–0199, twerym@nhlbi.nih.gov. Information is also available on the Institute’s/Center’s home page: https:// www.nhlbi.nih.gov/about/committees/sdrab/, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.233, National Center for Sleep Disorders Research; 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; 93.839, Blood Diseases and Resources Research, National Institutes of Health, HHS) [FR Doc. 2017–07054 Filed 4–7–17; 8:45 am] Dated: April 4, 2017. Michelle Trout, Program Analyst, Office of Federal Advisory Committee Policy. BILLING CODE 4140–01–P [FR Doc. 2017–07056 Filed 4–7–17; 8:45 am] PO 00000 BILLING CODE 4140–01–P Frm 00092 Fmt 4703 Sfmt 9990 E:\FR\FM\10APN1.SGM 10APN1

Agencies

[Federal Register Volume 82, Number 67 (Monday, April 10, 2017)]
[Notices]
[Pages 17268-17269]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-07058]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the U.S. patent applications listed below may be obtained by 
communicating with the indicated licensing contact James M. Robinson at 
the Technology Transfer and Intellectual Property Office, National 
Institute of Allergy and

[[Page 17269]]

Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology descriptions follows.

Compositions and Methods for Detecting Loa Loa

    Description of Technology: Loa loa is a filarial nematode estimated 
to infect 3-13 million people in Central and Western Africa. In parts 
of Africa, mass administration of ivermectin is common for 
onchocerciasis and lymphatic filariasis control. However, some 
individuals infected with Loa loa microfilariae in high densities are 
known to experience post-ivermectin severe adverse events, such as 
encephalopathy, coma, or even death. Therefore, diagnostic tools that 
can accurately identify and differentiate Loa loa microfilariae from 
other filarial infections are needed. Microscopic evaluation of blood 
samples is the only current diagnostic method used to detect Loa loa 
microfilaremia in endemic areas, and is impractical for widespread 
screening. Molecular based assays are useful and are quantitative, but 
require the use of sophisticated instrumentation.
    The inventors analyzed samples from Loa loa infected patients and 
uninfected controls, and have identified Loa loa microfilaria-specific 
antigens. The pending application claims a variety of means of 
detecting these antigens.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications:
     Diagnostics
Competitive Advantages:
     Highly specific to Loa loa microfilariae
     Highly sensitive
     Both diagnostic and quantitative
     Works with blood, urine, or saliva sample
Development Stage:
     Pre-Clinical

    Inventors: Thomas B. Nutman, NIAID, NIH; Sasisekhar Bennuru, NIAID, 
NIH; and Papa Makhtar Drame, NIAID, NIH.
    Publications: Drame, Papa, et al. 2016. Identification and 
Validation of Loa loa Microfilaria-Specific Biomarkers: A Rational 
Design Approach Using Proteomics and Novel Immunoassays. mBio, vol. 7 
no. 1 e02132-15.
    Intellectual Property: HHS Reference No. E-140-2015/0--US 
Provisional Patent Application No. 62/153,654 filed April 28, 2015; PCT 
Patent Application No. PCT/US2016/029673 filed April 28, 2016.
    Licensing Contact: James M. Robinson, 301-761-7542; 
James.Robinson4@nih.gov.
    Collaborative Research Opportunity: The Technology Transfer and 
Intellectual Property Office (TTIPO) is seeking parties interested in 
collaborative research to further develop, evaluate or commercialize a 
diagnostic means for detecting Loa loa microfilaria-specific antigens. 
For collaboration opportunities, please contact James M. Robinson, 301-
761-7542; James.Robinson4@nih.gov.

    Dated: March 28, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-07058 Filed 4-7-17; 8:45 am]
 BILLING CODE 4140-01-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.